<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": italic;} J Infect Public HealthJ Infect Public HealthJournal of" exact="Infection" post="and Public Health1876-03411876-035XThe Author(s). Published by Elsevier Ltd on"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="experienced coronavirus for the first time in 2002â€&quot;2003 through severe" exact="acute" post="respiratory syndrome (SARS), and in 2011, Middle East respiratory"/>
 <result pre="coronavirus for the first time in 2002â€&quot;2003 through severe acute" exact="respiratory" post="syndrome (SARS), and in 2011, Middle East respiratory syndrome"/>
 <result pre="for the first time in 2002â€&quot;2003 through severe acute respiratory" exact="syndrome" post="(SARS), and in 2011, Middle East respiratory syndrome (MERS)"/>
 <result pre="severe acute respiratory syndrome (SARS), and in 2011, Middle East" exact="respiratory" post="syndrome (MERS) for the first time. The causative agents"/>
 <result pre="acute respiratory syndrome (SARS), and in 2011, Middle East respiratory" exact="syndrome" post="(MERS) for the first time. The causative agents for"/>
 <result pre="contact [2,3], and people affected by COVID-19 suffer from severe" exact="respiratory" post="illness [4]. People who are elderly and have many"/>
 <result pre="[5,6]. There is no registered treatment or vaccine for this" exact="disease" post="[7]. For the treatment of affected people, limited urgent"/>
 <result pre="for this disease [7]. For the treatment of affected people," exact="limited" post="urgent use of chloroquine and hydroxychloroquine have been approved"/>
 <result pre="blood cells, which can travel throughout the body through the" exact="blood vessels." post="To monitor for invading microbes, the body exchanges cells"/>
 <result pre="ACE2 and have higher affinity [13]. It is transmitted through" exact="respiratory" post="droplets from coughing and sneezing and enters the nasal"/>
 <result pre="in SARS-CoV [15]. Next, the virus starts to propagate with" exact="limited" post="innate immune response and can be detected by nasal"/>
 <result pre="by nasal swabs. The virus then propagates and reaches the" exact="respiratory" post="tract, where it faces a more robust innate immune"/>
 <result pre="a more robust innate immune response. At this stage, the" exact="disease" post="is clinically manifest and an innate response cytokine may"/>
 <result pre="subsequent clinical course [16]. For beta and lambda infections, viral-infected" exact="epithelial" post="cells are a major source [17]. The disease will"/>
 <result pre="infections, viral-infected epithelial cells are a major source [17]. The" exact="disease" post="will be mild for 80% of the infected patients"/>
 <result pre="80% of the infected patients and mostly restricted to the" exact="upper" post="and conducting airways [18]. With conservative symptomatic therapy, these"/>
 <result pre="restricted to the upper and conducting airways [18]. With conservative" exact="symptomatic" post="therapy, these individuals may be monitored and monitored at"/>
 <result pre="monitored at home. Approximately 20% of the infected patients develop" exact="pulmonary" post="infiltrates and some of these develop very severe disease"/>
 <result pre="develop pulmonary infiltrates and some of these develop very severe" exact="disease" post="[19]. The mortality rate of severe patients with COVID-19"/>
 <result pre="were elderly patients in the severe group, with basic diseases." exact="Chronic" post="obstructive pulmonary disease, hypertension, malignant tumor, coronary heart disease,"/>
 <result pre="patients in the severe group, with basic diseases. Chronic obstructive" exact="pulmonary" post="disease, hypertension, malignant tumor, coronary heart disease, and chronic"/>
 <result pre="severe group, with basic diseases. Chronic obstructive pulmonary disease, hypertension," exact="malignant" post="tumor, coronary heart disease, and chronic kidney disease were"/>
 <result pre="with basic diseases. Chronic obstructive pulmonary disease, hypertension, malignant tumor," exact="coronary heart disease," post="and chronic kidney disease were more frequent in the"/>
 <result pre="basic diseases. Chronic obstructive pulmonary disease, hypertension, malignant tumor, coronary" exact="heart" post="disease, and chronic kidney disease were more frequent in"/>
 <result pre="obstructive pulmonary disease, hypertension, malignant tumor, coronary heart disease, and" exact="chronic" post="kidney disease were more frequent in the severe group"/>
 <result pre="pulmonary disease, hypertension, malignant tumor, coronary heart disease, and chronic" exact="kidney disease" post="were more frequent in the severe group than in"/>
 <result pre="disease, hypertension, malignant tumor, coronary heart disease, and chronic kidney" exact="disease" post="were more frequent in the severe group than in"/>
 <result pre="dies were over 60 years old. Forty patients had basic" exact="disease" post="out of 51 deaths (78.43%). Reports have demonstrated that"/>
 <result pre="who have comorbidities, especially hypertension, are at risk for severe" exact="disease" post="and death from SARS-CoV-2 infection [[21], [22], [23]]. Mechanism"/>
 <result pre="are at risk for severe disease and death from SARS-CoV-2" exact="infection" post="[[21], [22], [23]]. Mechanism of immune systems in the"/>
 <result pre="infections. As long as the immune system is functioning normally," exact="infections" post="such as COVID-19 go unnoticed. The three types of"/>
 <result pre="When the cells of the immune system become educated, they" exact="complete" post="their jobs by recirculating between central and peripheral lymphoid"/>
 <result pre="educated, they complete their jobs by recirculating between central and" exact="peripheral" post="lymphoid organs and migrating it and from sites of"/>
 <result pre="and from sites of injury via blood (Fig. 3 )." exact="Blood" post="carries naÃ¯ve and educated immune cells from one site"/>
 <result pre="exiting these nodes through outgoing lymphatic vessels [29]. Fig. 3" exact="Blood" post="in the pipeline of the immune system [29]. Many"/>
 <result pre="facility for the study of human beings in health and" exact="disease" post="where inherent heterogeneity dictates that large collections of samples"/>
 <result pre="into plasma cells, which then produce antibodies specific to a" exact="viral" post="antigen. A neutralizing nature antibody is efficient in fully"/>
 <result pre="the virus from entering into host cells to limit the" exact="infection" post="and plays a very intense protective role at the"/>
 <result pre="a very intense protective role at the later stage of" exact="infection" post="and prevents relapse of infection. By contrast, a cellular"/>
 <result pre="treatment, vaccination, and clinical approaches. Fig. 5 Progression of COVID-19" exact="infection" post="and potential adjuvant interventions [34]. Reasons for failure The"/>
 <result pre="The leading cause for mortality of patients with COVID-19 is" exact="respiratory" post="failure from acute respiratory distress syndrome [35]. Secondary hemophagocytic"/>
 <result pre="for mortality of patients with COVID-19 is respiratory failure from" exact="acute" post="respiratory distress syndrome [35]. Secondary hemophagocytic lymphohistiocytosis (sHLH) is"/>
 <result pre="mortality of patients with COVID-19 is respiratory failure from acute" exact="respiratory" post="distress syndrome [35]. Secondary hemophagocytic lymphohistiocytosis (sHLH) is characterized"/>
 <result pre="patients with COVID-19 is respiratory failure from acute respiratory distress" exact="syndrome" post="[35]. Secondary hemophagocytic lymphohistiocytosis (sHLH) is characterized by fulminant"/>
 <result pre="COVID-19 is respiratory failure from acute respiratory distress syndrome [35]." exact="Secondary" post="hemophagocytic lymphohistiocytosis (sHLH) is characterized by fulminant and fatal"/>
 <result pre="is respiratory failure from acute respiratory distress syndrome [35]. Secondary" exact="hemophagocytic lymphohistiocytosis" post="(sHLH) is characterized by fulminant and fatal hypercytokinemia with"/>
 <result pre="and fatal hypercytokinemia with multiorgan failure, and it is underrecognized." exact="Viral" post="infection triggers sHLH and occurs in 3.7%â€&quot;4.3% of sepsis"/>
 <result pre="fatal hypercytokinemia with multiorgan failure, and it is underrecognized. Viral" exact="infection" post="triggers sHLH and occurs in 3.7%â€&quot;4.3% of sepsis cases"/>
 <result pre="sHLH, resembled by a cytokine profile, is associated with COVID-19" exact="disease" post="severity, characterized by increased interleukin (IL)-2, IL-7, interferon-inducible protein"/>
 <result pre="interferon-inducible protein 10, granulocyte-colony stimulating factor, macrophage inflammatory protein 1-," exact="monocyte" post="chemoattractant protein 1, and tumor necrosis factor- (TNF-) [38]."/>
 <result pre="factor, macrophage inflammatory protein 1-, monocyte chemoattractant protein 1, and" exact="tumor" post="necrosis factor- (TNF-) [38]. A recent retrospective fatality predictorâ€™s"/>
 <result pre="vaccine encoding S protein Moderna Phase I (NCT04283461) Ad5-nCoV Adenovirus" exact="type 5" post="vector that expresses S protein CanSino Biologicals Phase I"/>
 <result pre="I (NCT04276896) expressing synthetic minigene based on domains of selected" exact="viral" post="proteins; administered with antigen-specific CTLs Medical Institute Pathogen-specific aAPC"/>
 <result pre="lentiviral vector expressing synthetic minigene based on domains of selected" exact="viral" post="proteins Shenzhen Geno-Immune Medical Institute Phase I (NCT04299724) According"/>
 <result pre="The most common adverse effects were fever, fatigue, headache, and" exact="muscle" post="pain. One study demonstrated that [42] for the treatment"/>
 <result pre="is effective. The survival rate of patients with SARS of" exact="viral" post="etiology has been improved with this treatment [43]. Pre-donation"/>
 <result pre="14 days are the convalescent donors. Individuals from the tropical" exact="disease" post="areas were also excluded. Plasma, approximately 400â€&quot;800Â mL, was"/>
 <result pre="events to convalescent plasma in different epidemics. Table 2 Country" exact="Viral" post="etiology Adverse events References China COVID-19 None [47] China"/>
 <result pre="Nausea, skin erythema, fever. No major adverse events. [60] China" exact="Influenza A (H1N1)" post="None [61] China Influenza A (H1N1) None [62] China"/>
 <result pre="adverse events. [60] China Influenza A (H1N1) None [61] China" exact="Influenza A (H1N1)" post="None [62] China Influenza A (H1N1) None [63] China"/>
 <result pre="(H1N1) None [61] China Influenza A (H1N1) None [62] China" exact="Influenza A (H1N1)" post="None [63] China Influenza A (H1N1) None [64] Because"/>
 <result pre="(H1N1) None [62] China Influenza A (H1N1) None [63] China" exact="Influenza A (H1N1)" post="None [64] Because there is no definite and specific"/>
 <result pre="treatment of patients with COVID-19. For the treatment of Ebola" exact="virus infection" post="in 2017, Gilead Sciences synthesized and developed remdesivir, and"/>
 <result pre="of patients with COVID-19. For the treatment of Ebola virus" exact="infection" post="in 2017, Gilead Sciences synthesized and developed remdesivir, and"/>
 <result pre="chemical structures and are often used for the treatment of" exact="malaria" post="erythematosus and rheumatoid arthritis [66]. Lopinavir is another drug,"/>
 <result pre="are often used for the treatment of malaria erythematosus and" exact="rheumatoid arthritis" post="[66]. Lopinavir is another drug, which was administered and"/>
 <result pre="often used for the treatment of malaria erythematosus and rheumatoid" exact="arthritis" post="[66]. Lopinavir is another drug, which was administered and"/>
 <result pre="used in Russia and China for the treatment of prophylaxis," exact="infections" post="associated with influenza A and B, and other arbovirus"/>
 <result pre="developed by Fujifilm Toyama Chemical, Japan, in 2014, for treating" exact="avian influenza" post="resistant to neuraminidase inhibitors [69]. Oseltamivir is used to"/>
 <result pre="and COVID-19. Table 3 Off-label drugs against SARS-CoV-2 and COVID-19" exact="disease" post="[92]. Table 3 Drug Class Target Dosage References Camostat"/>
 <result pre="per oral or intravenous [[83], [84], [85]] Lopinavir/ritonavir Antiviral drug" exact="Viral" post="proteases 400Â mg lopinavir and 100 mg ritonavir twice"/>
 <result pre="animals with S protein-oriented vaccines is very effective in preventing" exact="infection" post="by homologous coronavirus [94]. If human cells are infected"/>
 <result pre="more than 100 COVID-19 cases [104]. The highest number of" exact="infections" post="was found in seven countries: the United States (nÂ"/>
 <result pre="no immune persons in the population. It indicates that any" exact="partial" post="pre-existing immunity to the infecting elements is able to"/>
 <result pre="infecting elements is able to decrease the number of expected" exact="secondary" post="cases emerging. Whenever this perception is applied in case"/>
 <result pre="(Rt) (95% CI), (nÂ =Â 32) Minimum proportion (%) of" exact="total" post="population required to recover from COVID-19 to confer immunity"/>
 <result pre="to SARS-CoV-2. Except for patient #11, the followed-up patients had" exact="lower" post="levels of neutralizing antibody titers than the recently discharged"/>
 <result pre="poses many threats. A different door is used for every" exact="infection" post="to enter a cell, and blocking these routes of"/>
 <result pre="cell, and blocking these routes of entry can stop an" exact="infection" post="before it begins. The immune system neutralizes an infection"/>
 <result pre="an infection before it begins. The immune system neutralizes an" exact="infection" post="by producing antibodies; however, this must be conducted at"/>
 <result pre="conducted at the proper time. An immune systemâ€&quot;ideallyâ€&quot;must stop an" exact="infection" post="before it has established a foothold in the body"/>
 <result pre="[109], [110], [111]]. Fig. 8 The adaptive immune response to" exact="infection" post="[111]. Suggested food, vaccination, drugs, and supplementary for the"/>
 <result pre="a strong immune system and have a reduced risk of" exact="chronic" post="illness, infectious diseases. Vitamins and minerals are vital. Vitamin"/>
 <result pre="immune system and have a reduced risk of chronic illness," exact="infectious diseases." post="Vitamins and minerals are vital. Vitamin B, insoluble in"/>
 <result pre="are vital. Vitamin B, insoluble in water, protects from infection." exact="Vitamin C" post="protects from flu-like symptoms [112]. Insufficient vitamin D and"/>
 <result pre="Insufficient vitamin D and vitamin E can lead to coronavirus" exact="infection" post="[113]. Vitamin D can be found in sunlight, and"/>
 <result pre="Allergy Immunol2020 2Yan-RongGuoQing-DongCaoZhong-SiHongYuan-YangTanShou-DengChenHong-JunJinThe origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak â€&quot; an update on the statusMil"/>
 <result pre="coronavirus infected pneumoniaN Engl J Med192020 4GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med2020 5KwokK.O.LaiF.WeiW.I.WongS.Y.S.TangJ.W.T.Herd immunity â€&quot;"/>
 <result pre="protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe" exact="acute" post="respiratory syndromeClin Chem5120052333234016195357 17HancockA.S.StairikerC.J.BoesteanuA.C.Transcriptome analysis of infected and bystander"/>
 <result pre="(CXCL-10) and other chemokines predicts adverse outcome in severe acute" exact="respiratory" post="syndromeClin Chem5120052333234016195357 17HancockA.S.StairikerC.J.BoesteanuA.C.Transcriptome analysis of infected and bystander type"/>
 <result pre="acute respiratory syndromeClin Chem5120052333234016195357 17HancockA.S.StairikerC.J.BoesteanuA.C.Transcriptome analysis of infected and bystander" exact="type 2" post="alveolar epithelial cells during influenza A virus infection reveals"/>
 <result pre="Chem5120052333234016195357 17HancockA.S.StairikerC.J.BoesteanuA.C.Transcriptome analysis of infected and bystander type 2 alveolar" exact="epithelial" post="cells during influenza A virus infection reveals in vivo"/>
 <result pre="and bystander type 2 alveolar epithelial cells during influenza A" exact="virus infection" post="reveals in vivo Wnt pathway downregulationJ Virol922018e01325-18 18Wu Z,"/>
 <result pre="bystander type 2 alveolar epithelial cells during influenza A virus" exact="infection" post="reveals in vivo Wnt pathway downregulationJ Virol922018e01325-18 18Wu Z,"/>
 <result pre="McGoogan JM. Characteristics of and important lessons from the coro-navirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and Prevention. JAMA 2020 [in press]. 19MasonR.J.Pathogenesis of"/>
 <result pre="20WangD.HuB.HuC.ChangHuZhuF.LiuX.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA2020[Published online 7 February 2020] 21ChenN.ZhouM.DongX.QuJ.GongF.HanY.Epidemiological and"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet2020(January) 22HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of"/>
 <result pre="VimalK.Saxena ShailendraK.Host immune response and immunobiology of human SARS-CoV-2 infectionCoronavirus" exact="disease" post="2019 (COVID-19)20204353 31LuR.ZhaoX.LiJ.NiuP.YangB.WuH.Genomic characterisation and epidemiology of 2019 novel"/>
 <result pre="con-valescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis2112015809025030060"/>
 <result pre="studies of SARSJ Virol942020e00127â€&quot;220 45HancockA.S.StairikerC.J.BoesteanuA.C.Transcriptome analysis of infected and bystander" exact="type 2" post="alveolar epithelial cells during influenza A virus infection reveals"/>
 <result pre="Virol942020e00127â€&quot;220 45HancockA.S.StairikerC.J.BoesteanuA.C.Transcriptome analysis of infected and bystander type 2 alveolar" exact="epithelial" post="cells during influenza A virus infection reveals in vivo"/>
 <result pre="and bystander type 2 alveolar epithelial cells during influenza A" exact="virus infection" post="reveals in vivo Wnt pathway downregulationJ Virol922018e01325-18 46ManuelRojasYhojanRodrÃ­guezabMonsalvea DianaM.AcostaAmpudia"/>
 <result pre="bystander type 2 alveolar epithelial cells during influenza A virus" exact="infection" post="reveals in vivo Wnt pathway downregulationJ Virol922018e01325-18 46ManuelRojasYhojanRodrÃ­guezabMonsalvea DianaM.AcostaAmpudia"/>
 <result pre="47BinZhangShuyiLiuTanTan.WenhuiHuangYuhaoDongLuyanChenTreatment with convalescent plasma for critically ill patients with SARS-CoV-2" exact="infection" post="chest2020 48ShenC.WangZ.ZhaoF.YangY.LiJ.YuanJ.Treatment of 5 critically ill patients with Covid-19"/>
 <result pre="of convalescent plasma therapy in two patients with COVID-19 with" exact="acute" post="respiratory distress syndrome in KoreaJ Korean Med Sci352020e14932281317 52SooY.O.Y.ChengY.WongR.HuiD.S.LeeC.K.TsangK.K.S.Retrospective"/>
 <result pre="convalescent plasma therapy in two patients with COVID-19 with acute" exact="respiratory" post="distress syndrome in KoreaJ Korean Med Sci352020e14932281317 52SooY.O.Y.ChengY.WongR.HuiD.S.LeeC.K.TsangK.K.S.Retrospective comparison"/>
 <result pre="therapy in two patients with COVID-19 with acute respiratory distress" exact="syndrome" post="in KoreaJ Korean Med Sci352020e14932281317 52SooY.O.Y.ChengY.WongR.HuiD.S.LeeC.K.TsangK.K.S.Retrospective comparison of convalescent"/>
 <result pre="Infect Dis242005444615616839 54NieQ.-H.-H.LuoX.-D.-D.HuiW.-L.-L.Advances in clinical diagnosis and treatment of severe" exact="acute" post="respiratory syndrome worldJ Gastroenterol9200311391143 55YehK.-M.-M.ChiuehT.-S.-S.SiuL.K.LinJ.-C.-C.ChanP.K.S.PengM.-Y.-Y.Experi-ence of using convalescent plasma"/>
 <result pre="Dis242005444615616839 54NieQ.-H.-H.LuoX.-D.-D.HuiW.-L.-L.Advances in clinical diagnosis and treatment of severe acute" exact="respiratory" post="syndrome worldJ Gastroenterol9200311391143 55YehK.-M.-M.ChiuehT.-S.-S.SiuL.K.LinJ.-C.-C.ChanP.K.S.PengM.-Y.-Y.Experi-ence of using convalescent plasma for"/>
 <result pre="54NieQ.-H.-H.LuoX.-D.-D.HuiW.-L.-L.Advances in clinical diagnosis and treatment of severe acute respiratory" exact="syndrome" post="worldJ Gastroenterol9200311391143 55YehK.-M.-M.ChiuehT.-S.-S.SiuL.K.LinJ.-C.-C.ChanP.K.S.PengM.-Y.-Y.Experi-ence of using convalescent plasma for severe"/>
 <result pre="syndrome worldJ Gastroenterol9200311391143 55YehK.-M.-M.ChiuehT.-S.-S.SiuL.K.LinJ.-C.-C.ChanP.K.S.PengM.-Y.-Y.Experi-ence of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospitalJ"/>
 <result pre="worldJ Gastroenterol9200311391143 55YehK.-M.-M.ChiuehT.-S.-S.SiuL.K.LinJ.-C.-C.ChanP.K.S.PengM.-Y.-Y.Experi-ence of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospitalJ Antimicrob"/>
 <result pre="Gastroenterol9200311391143 55YehK.-M.-M.ChiuehT.-S.-S.SiuL.K.LinJ.-C.-C.ChanP.K.S.PengM.-Y.-Y.Experi-ence of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospitalJ Antimicrob Chemother56200591992216183666"/>
 <result pre="diagnosis and therapy of first cluster of patients with severe" exact="acute" post="res-piratory syndrome in Beijing areaZhonghua Yi Xue Za Zhi8320031018102212899773"/>
 <result pre="therapy of first cluster of patients with severe acute res-piratory" exact="syndrome" post="in Beijing areaZhonghua Yi Xue Za Zhi8320031018102212899773 57KongL.Letter to"/>
 <result pre="Za Zhi8320031018102212899773 57KongL.Letter to editorTransfus Apher Sci29200310112952008 58WongV.W.S.DaiD.WuA.K.L.SungJ.J.Y.Treatment of severe" exact="acute" post="respiratory syndrome with convalescent plasma Hong KongMed J92003199201 59KoJ.-H.-H.SeokH.ChoS.Y.HaY.E.BaekJ.Y.KimS.H.Challenges"/>
 <result pre="Zhi8320031018102212899773 57KongL.Letter to editorTransfus Apher Sci29200310112952008 58WongV.W.S.DaiD.WuA.K.L.SungJ.J.Y.Treatment of severe acute" exact="respiratory" post="syndrome with convalescent plasma Hong KongMed J92003199201 59KoJ.-H.-H.SeokH.ChoS.Y.HaY.E.BaekJ.Y.KimS.H.Challenges of"/>
 <result pre="57KongL.Letter to editorTransfus Apher Sci29200310112952008 58WongV.W.S.DaiD.WuA.K.L.SungJ.J.Y.Treatment of severe acute respiratory" exact="syndrome" post="with convalescent plasma Hong KongMed J92003199201 59KoJ.-H.-H.SeokH.ChoS.Y.HaY.E.BaekJ.Y.KimS.H.Challenges of convalescent"/>
 <result pre="J92003199201 59KoJ.-H.-H.SeokH.ChoS.Y.HaY.E.BaekJ.Y.KimS.H.Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: a single centre experienceAntivir Ther23201861762229923831 60van GriensvenJ.EdwardsT.de"/>
 <result pre="Ther23201861762229923831 60van GriensvenJ.EdwardsT.de LamballerieX.SempleM.G.GallianP.BaizeS.Evaluation of convalescent plasma for Ebola virus" exact="disease" post="in GuineaN Engl J Med3742016334226735992 61HungI.F.ToK.K.LeeC.-K.-K.LeeC.-K.-L.ChanK.YanW.-W.-W.Convalescent plasma treatment reduced"/>
 <result pre="J16201044745421135421 63YuH.GaoZ.FengZ.ShuY.XiangN.ZhouL.Clinical characteristics of 26 human cases of highly pathogenic" exact="avian influenza" post="A (H5N1) virus infection in ChinaPLoS One32008e298518716658 64KongL.K.ZhouB.P.Successful treatment"/>
 <result pre="26 human cases of highly pathogenic avian influenza A (H5N1)" exact="virus infection" post="in ChinaPLoS One32008e298518716658 64KongL.K.ZhouB.P.Successful treatment of avian influenza with"/>
 <result pre="human cases of highly pathogenic avian influenza A (H5N1) virus" exact="infection" post="in ChinaPLoS One32008e298518716658 64KongL.K.ZhouB.P.Successful treatment of avian influenza with"/>
 <result pre="A (H5N1) virus infection in ChinaPLoS One32008e298518716658 64KongL.K.ZhouB.P.Successful treatment of" exact="avian influenza" post="with convalescent plasmaHong Kong Med J122006489 65SiegelD.HuiH.C.DoerfflerE.ClarkeM.O.ChunK.ZhangL.Discovery and synthesis"/>
 <result pre="and ritonavir) tablet.12/2019. 68BoriskinY.S.LenevaI.A.PecheurE.I.PolyakS.J.Arbidol: a broad-spectrum antiviral compound that blocks" exact="viral" post="fusionCurr Med Chem15102008997100518393857 69FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor"/>
 <result pre="fusionCurr Med Chem15102008997100518393857 69FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Jpn Acad, Ser B, Phys Biol Sci9372017449463"/>
 <result pre="a clinically proven protease receptorCell2020(March) 74SaiJ.K.SuyamaM.KubokawaY.MatsumuraY.InamiK.WatanabeS.Efficacy of camostat mesilate against" exact="dyspepsia" post="associated with non-alcoholic mild pancreatic diseaseJ Gastroenterol45320103353411988 98â€&quot;10419876587 75HirotaM.ShimosegawaT.KitamuraK.TakedaK.TakeyamaY.MayumiT.Continuous"/>
 <result pre="administration of the protease inhibitor nafamostat mesilate for predicted severe" exact="acute" post="pan-creatitis: a multicenter, randomized, open-label, phase 2 trialJ Gastroenterol553202034235231758329"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020(March) 79GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloro-quine and"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020(March) 79GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloro-quine and azithromycin"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020(March) 79GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloro-quine and azithromycin as"/>
 <result pre="coro-navirusesSci Transl Med93962017eaal3653 82MulanguS.DoddL.E.DaveyR.T.Thsihani MbayaO.ProschanM.MukadiD.A.Randomized controlled trial of Ebola virus" exact="disease" post="therapeuticsN Engl J Med3812420192293230331774950 83GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.Compassion-ate use of remdesivir for"/>
 <result pre="Engl J Med2020(March) 87WangZ.YangB.LiQ.WenL.ZhangR.Clinical features of 69 cases with coronavirus" exact="disease" post="2019 in Wuhan, ChinaClin Infect Dis2020(March) 88DengL.LiC.ZengQ.LiuX.LiX.ZhangH.Arbidol combined with"/>
 <result pre="88DengL.LiC.ZengQ.LiuX.LiX.ZhangH.Arbidol combined with LPV/r versus LPV/r alone against corona virus" exact="disease" post="2019: a retrospective cohort studyJ Infect2020(March) 89SissokoD.LaouenanC.FolkessonE.MLebingÂ´A.B.BeavoguiA.H.BaizeS.Exper-imental treatment with"/>
 <result pre="cohort studyJ Infect2020(March) 89SissokoD.LaouenanC.FolkessonE.MLebingÂ´A.B.BeavoguiA.H.BaizeS.Exper-imental treatment with favipiravir for Ebola virus" exact="disease" post="(the JIKI Trial): a historically controlled, single-arm proof-of-concept trial"/>
 <result pre="infectionJ Leukoc Biol712002163211781377 111NonneckeB.J.McGillJ.L.RidpathJ.F.SaccoR.E.LippolisJ.D.ReinhardtT.A.Acute phase response elicited by experimental bovine" exact="diarrhea" post="virus (BVDV) infec-tion is associated with decreased vitamin D"/>
 <result pre="112Wessling-ResnickM.Crossing the Iron Gate: why and how transferrin recep-tors mediate" exact="viral" post="entryAnnu Rev Nutr38201843145829852086 113JayaweeraJ.ReyesM.JosephA.Childhood iron deficiency anemia leads to"/>
 <result pre="and how transferrin recep-tors mediate viral entryAnnu Rev Nutr38201843145829852086 113JayaweeraJ.ReyesM.JosephA.Childhood" exact="iron deficiency anemia" post="leads to recurrent respiratory tract infections and gastroenteritisSci Rep920191263731477792"/>
 <result pre="how transferrin recep-tors mediate viral entryAnnu Rev Nutr38201843145829852086 113JayaweeraJ.ReyesM.JosephA.Childhood iron" exact="deficiency" post="anemia leads to recurrent respiratory tract infections and gastroenteritisSci"/>
 <result pre="transferrin recep-tors mediate viral entryAnnu Rev Nutr38201843145829852086 113JayaweeraJ.ReyesM.JosephA.Childhood iron deficiency" exact="anemia" post="leads to recurrent respiratory tract infections and gastroenteritisSci Rep920191263731477792"/>
 <result pre="viral entryAnnu Rev Nutr38201843145829852086 113JayaweeraJ.ReyesM.JosephA.Childhood iron deficiency anemia leads to" exact="recurrent" post="respiratory tract infections and gastroenteritisSci Rep920191263731477792 114MaaresM.HaaseH.Zinc and immunity:"/>
 <result pre="entryAnnu Rev Nutr38201843145829852086 113JayaweeraJ.ReyesM.JosephA.Childhood iron deficiency anemia leads to recurrent" exact="respiratory" post="tract infections and gastroenteritisSci Rep920191263731477792 114MaaresM.HaaseH.Zinc and immunity: an"/>
 <result pre="Nutr38201843145829852086 113JayaweeraJ.ReyesM.JosephA.Childhood iron deficiency anemia leads to recurrent respiratory tract" exact="infections" post="and gastroenteritisSci Rep920191263731477792 114MaaresM.HaaseH.Zinc and immunity: an essential interrelationArch"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Mil Med Res72020432029004 116CrossM.L.GillH.S.Immunomodulatory properties of milkBr J"/>
</results>
